(Q33400988)

English

Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

object named as

Corey J Langer

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

object named as

Tracey L Evans

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

James P Stevenson

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Robert A Somer

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kumar Rajagopalan

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kimberly Krieger

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mona Jacobs-Small

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nikolas Dyanick

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Barry Milcarek

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Susan Coakley

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Suzanne Walker

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Beth Eaby-Sandy

12

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Alexandre Hageboutros

13

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

27 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

118

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

22

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

5580-5587

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27576

21 January 2018

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27576

21 January 2018

Three-arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group--EORTC 08975.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27576

21 January 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27576

21 January 2018

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27576

21 January 2018

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27576

21 January 2018

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27576

21 January 2018

Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27576

21 January 2018

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27576

21 January 2018

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27576

21 January 2018

A randomized phase II trial of pemetrexed/gemcitabine/bevacizumab or pemetrexed/carboplatin/bevacizumab in the first-line treatment of elderly patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27576

21 January 2018

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.27576

21 January 2018

Identifiers

10.1002/CNCR.27576

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33400988&oldid=1915882305"